HealthQuill Acquisition
Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an upfront payment of $850 million.
Drugs Health Pharma

Roche arm to buy breast cancer portfolio from Regor for $850 million

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.

Read More
US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltdā€™s arm ā€” Dermavant Sciences Ltd., specialising in immuno-dermatology ā€” for $1.2 billion.
Drugs Health Pharma

Organon & Co to buy Riovant’s arm Dermavant Sciences for $1.2 billion

US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltdā€™s arm ā€” Dermavant Sciences Ltd., specialising in immuno-dermatology ā€” for $1.2 billion.

Read More
EQT Private Capital Asia will acquire a controlling stake in GeBBS Healthcare Solutions, a provider of healthcare outsourcing solutions from ChrysCapital, according to a statement from EQT.
Drugs Health Pharma

EQT Private Capital Asia to acquire controlling stake in US-based GeBBS

EQT Private Capital Asia will acquire a controlling stake in GeBBS Healthcare Solutions, a provider of healthcare outsourcing solutions from ChrysCapital, according to.

Read More
McKesson Corporation, theĀ ninth-largestĀ company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its oncology portfolio.
Drugs Health Pharma

McKesson Corp., to acquire Core Ventures for $2.4 billion in cash

McKesson Corporation, theĀ ninth-largestĀ company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its.

Read More
Johnson & Johnson plans to acquire Israelā€™s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Health Pharma

J&J plans to acquire Israelā€™s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israelā€™s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

Read More
Indiaā€™s Mankind Pharma will buy Mumbai-based Bharat Serums and Vaccines for 136 billion rupees ($1.63 billion), according to a company statement.
Drugs Health Pharma

Mankind Pharma buys Bharat Serum and Vaccines for $1.6 billion

Indiaā€™s Mankind Pharma will buy Mumbai-based Bharat Serums and Vaccines for 136 billion rupees ($1.63 billion), according to a company statement.

Read More
Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to a company statement.
Drugs Health Pharma

US-based Agilent Technologies to acquire Canadaā€™s Biovectra for $925m

HQ Team July 23, 2024: Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to.

Read More
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
Drugs Health Pharma

AstraZeneca completes $2.4 billion acquisition of Fusion Pharma

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

Read More
Johnson & JohnsonĀ has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.
Drugs Health Pharma

J & J to buy rights for experimental skin disorder drug for $1.25 billion

Johnson & JohnsonĀ has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.

Read More
Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to a statement.
Drugs Health Pharma

Johnson & Johnson to buy Proteologix Inc., for $850 million in cash

HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.

Read More